INTANGIBLE ASSETS, NET (Tables)

12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018:

The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018:

	December 31, 2019
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
Approved hormone
therapy drug
candidate patents	$	3,463,082	$	(478,983	)	$	2,984,099		13
Hormone therapy drug
candidate patents
(pending)		1,979,299		—			1,979,299		n/a
Non-amortizable intangible
assets:
Multiple trademarks		294,813		—			294,813		indefinite
TOTAL	$	5,737,194	$	(478,983	)	$	5,258,211

	December 31, 2018
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
OPERA software patent	$	31,951	$	(10,484	)	$	21,467		10.75
Development costs of
corporate website		91,743		(91,743	)		—		n/a
Approved hormone
therapy drug
candidate patents		2,234,129		(282,485	)		1,951,644		14
Hormone therapy drug
candidate patents
(pending)		1,855,279		—			1,855,279		n/a
Non-amortizable intangible
assets:
Multiple trademarks		264,289		—			264,289		indefinite
TOTAL	$	4,477,391	$	(384,712	)	$	4,092,679

Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:

Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:

Year Ending December 31,	Estimated Amortization
2020	$229,546
2021	$229,546
2022	$229,546
2023	$229,546
2024	$229,546